ID: ALA4202865

Max Phase: Preclinical

Molecular Formula: C25H27N5O3

Molecular Weight: 445.52

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(C)Oc1ccc(CO)cc1Nc1nccc(-c2cc(C#N)c3c(c2)[C@@](C)(CO)CN3)n1

Standard InChI:  InChI=1S/C25H27N5O3/c1-15(2)33-22-5-4-16(12-31)8-21(22)30-24-27-7-6-20(29-24)17-9-18(11-26)23-19(10-17)25(3,14-32)13-28-23/h4-10,15,28,31-32H,12-14H2,1-3H3,(H,27,29,30)/t25-/m1/s1

Standard InChI Key:  RISSKZZAQYAEKW-RUZDIDTESA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 445.52

Molecular Weight (Monoisotopic): 445.2114

AlogP: 3.71

#Rotatable Bonds: 7

Polar Surface Area: 123.32

Molecular Species: NEUTRAL

HBA: 8

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.50

CX Basic pKa: 2.16

CX LogP: 2.88

CX LogD: 2.88

Aromatic Rings: 3

Heavy Atoms: 33

QED Weighted: 0.43

Np Likeness Score: -0.39

References

1. Kargbo RB..  (2017)  New Substituted Cyanoindoline Derivatives as MAP3K14 Kinase Inhibitors for the Treatment of Cancer and Autoimmune Disorders.,  8  (9): [PMID:28947934] [10.1021/acsmedchemlett.7b00330]

Source

Source(1):

• Scientific Literature